Biostate AI Secures $12M for AI Driven RNA Sequencing
Houston based Biostate AI has successfully closed a $12 million Series A funding round led by Accel, with participation from prominent investors including Gaingels, Mana Ventures, and influential biotech angel investors.
Founded by experienced entrepreneurs and academic experts, Biostate AI is at the forefront of combining generative AI with advanced RNA sequencing to create next generation molecular diagnostic tools.
Biostate AI Powers Personalized Treatment with $12M Raise
The fresh capital will enable Biostate AI to accelerate development and scaling of its cost effective, AI powered RNA sequencing platform.
This platform aims to provide highly detailed molecular profiles, empowering clinicians with precise, personalized insights for complex diseases like cancer, autoimmune disorders, and beyond.
In addition to expanding its engineering team, Biostate AI plans to deepen collaborations with research institutions and healthcare providers globally.
Their proprietary technology is designed to unlock hidden RNA signatures that traditional methods often miss, potentially transforming disease diagnosis and treatment paradigms.
With this funding boost, Biostate AI is poised to lead the charge in RNA driven precision medicine, delivering faster, more affordable, and highly accurate diagnostic solutions worldwide.
